Pirtobrutinib
- Generic Name
- Pirtobrutinib
- Brand Names
- Jaypirca
- Drug Type
- Small Molecule
- Chemical Formula
- C22H21F4N5O3
- CAS Number
- 2101700-15-4
- Unique Ingredient Identifier
- JNA39I7ZVB
- Background
Pirtobrutinib is a small molecule and a highly selective non-covalent inhibitor of Bruton’s tyrosine kinase (BTK). Its high selectivity has been associated with lower discontinuation rates due to adverse events and a lower incidence of atrial fibrillation. Unlike BTK covalent inhibitors, such as ibrutinib, that bind to the cysteine 481 (Cys481) amino acid wi...
- Indication
Pirtobrutinib is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.
- Associated Conditions
- Refractory Mantle Cell Lymphoma, Relapsed Mantle Cell Lymphoma
- Associated Therapies
- -
No news found
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath